

Global PD-1/PD-L1 Checkpoint Inhibitors Market Growth 2026-2032

<https://marketpublishers.com/r/G614EB0C728EEN.html>

Date: January 2026

Pages: 87

Price: US\$ 3,660.00 (Single User License)

ID: G614EB0C728EEN

Abstracts

The global PD-1/PD-L1 Checkpoint Inhibitors market size is predicted to grow from US\$ 56890 million in 2025 to US\$ 121100 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.

PD-1/PD-L1 checkpoint inhibitors are a class of immuno-oncology therapies designed to block the immune-suppressive signaling pathway that tumors exploit to deactivate T-cell-mediated antitumor immunity. These agents address the unmet need of patients whose tumors are resistant or poorly responsive to conventional chemotherapy and targeted therapies. The concept emerged as researchers uncovered how malignant cells overexpress PD-L1 or engage PD-1 on T cells to evade immune surveillance; the development of monoclonal antibodies capable of binding and blocking these proteins led to a therapeutic breakthrough, with the first approvals in 2014 reshaping cancer treatment worldwide. Their development and manufacturing rely on an upstream supply chain that includes cell line development materials, recombinant protein expression systems, culture media, buffers, filtration consumables, bioreactors, and aseptic filling components. This also covers nucleic acid materials for antibody engineering, analytical reagents, and instrumentation essential for quality control, forming a comprehensive upstream ecosystem that ensures product consistency, safety, and clinical performance. In 2024, global sales of PD-1/PD-L1 checkpoint inhibitors reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.

From a market perspective, the PD-1/PD-L1 inhibitor landscape has transitioned from a narrow set of indications to a broad, heterogeneous adoption across cancer types and treatment lines, accompanied by an increasingly crowded supplier ecosystem. Market dynamics are shaped not only by competing products but also by a growing ancillary

industry of diagnostic developers, contract manufacturers and service providers that support clinical translation and commercialization. Regional differences in clinical guidelines, payer policies and healthcare infrastructure further lead to heterogeneous uptake patterns, even as overall clinical familiarity and guideline inclusion continue to strengthen usage.

Looking ahead, two complementary trends will dominate: precision immunotherapy and rational combinations. Precision approaches that integrate tumor genomics, immune microenvironment profiling and predictive biomarkers will refine patient selection and improve benefit/risk ratios, while combination regimens aim to broaden responder populations and delay or overcome resistance. Concurrently, platform innovations ? such as engineered antibodies, bispecific constructs, long-acting formats and localized delivery systems ? will diversify the therapeutic toolbox and open niche application opportunities.

Key growth drivers include persistent unmet clinical needs, robust R&D funding, and evolving regulatory frameworks that increasingly accommodate breakthrough immunotherapies; clinician experience and patient advocacy also accelerate adoption. Major constraints remain: intrinsic and acquired resistance in certain tumor types, uneven access driven by cost and reimbursement variability, and the high technical and capital barriers of biologics development and manufacturing. The interplay among scientific advances, payer decisions and real-world evidence generation will determine how rapidly and equitably these therapies diffuse into broader oncology practice.

LP Information, Inc. (LPI) ' newest research report, the ?PD-1/PD-L1 Checkpoint Inhibitors Industry Forecast? looks at past sales and reviews total world PD-1/PD-L1 Checkpoint Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected PD-1/PD-L1 Checkpoint Inhibitors sales for 2026 through 2032. With PD-1/PD-L1 Checkpoint Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world PD-1/PD-L1 Checkpoint Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global PD-1/PD-L1 Checkpoint Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1/PD-L1 Checkpoint Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global PD-1/PD-L1 Checkpoint Inhibitors

market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1/PD-L1 Checkpoint Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1/PD-L1 Checkpoint Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of PD-1/PD-L1 Checkpoint Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

PD-1 Inhibitors

PD-L1 Inhibitors

Segmentation by Product Name:

Pembrolizumab

Nivolumab

Cemiplimab

Toripalimab

Sintilimab

Tislelizumab

Camrelizumab

Penpulimab

Retifanlimab

Zimberelimab

Atezolizumab

Durvalumab

Avelumab

Envafohimab

Adebrelimab

Segmentation by Dosage Strength:

100 mg / Vial

200 mg / Vial

240 mg / Vial

300 mg / Vial

Segmentation by Application:

Squamous Cell Skin Cancer

Non-small Cell Lung Cancer

Melanoma

Gastric Cancer

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Bristol Myers Squibb

Merck

Regeneron Pharmaceuticals

Roche

Pfizer

AstraZeneca

Hengrui Pharmaceuticals

Junshi Biosciences

Innovent

Key Questions Addressed in this Report

What is the 10-year outlook for the global PD-1/PD-L1 Checkpoint Inhibitors market?

What factors are driving PD-1/PD-L1 Checkpoint Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?
How do PD-1/PD-L1 Checkpoint Inhibitors market opportunities vary by end market size?
How does PD-1/PD-L1 Checkpoint Inhibitors break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for PD-1/PD-L1 Checkpoint Inhibitors by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for PD-1/PD-L1 Checkpoint Inhibitors by Country/Region, 2021, 2025 & 2032
- 2.2 PD-1/PD-L1 Checkpoint Inhibitors Segment by Type
 - 2.2.1 PD-1 Inhibitors
 - 2.2.2 PD-L1 Inhibitors
 - 2.2.3 PD-1/PD-L1 Checkpoint Inhibitors Sales by Type
 - 2.2.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sale Price by Type (2021-2026)
- 2.3 PD-1/PD-L1 Checkpoint Inhibitors Segment by Application
 - 2.3.1 Squamous Cell Skin Cancer
 - 2.3.2 Non-small Cell Lung Cancer
 - 2.3.3 Melanoma
 - 2.3.4 Gastric Cancer
 - 2.3.5 Other
 - 2.3.6 PD-1/PD-L1 Checkpoint Inhibitors Sales by Application
 - 2.3.6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sale Market Share by Application (2021-2026)

2.3.6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue and Market Share by Application (2021-2026)

2.3.6.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Breakdown Data by Company

3.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Sales by Company (2021-2026)

3.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Company (2021-2026)

3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Revenue by Company (2021-2026)

3.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Company (2021-2026)

3.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Company (2021-2026)

3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sale Price by Company

3.4 Key Manufacturers PD-1/PD-L1 Checkpoint Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers PD-1/PD-L1 Checkpoint Inhibitors Product Location Distribution

3.4.2 Players PD-1/PD-L1 Checkpoint Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PD-1/PD-L1 CHECKPOINT INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic PD-1/PD-L1 Checkpoint Inhibitors Market Size by Geographic Region (2021-2026)

4.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Sales by Geographic Region (2021-2026)

4.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country/Region

(2021-2026)

4.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Sales by Country/Region

(2021-2026)

4.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Revenue by Country/Region

(2021-2026)

4.3 Americas PD-1/PD-L1 Checkpoint Inhibitors Sales Growth

4.4 APAC PD-1/PD-L1 Checkpoint Inhibitors Sales Growth

4.5 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Growth

4.6 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Growth

5 AMERICAS

5.1 Americas PD-1/PD-L1 Checkpoint Inhibitors Sales by Country

5.1.1 Americas PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026)

5.1.2 Americas PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026)

5.2 Americas PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026)

5.3 Americas PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC PD-1/PD-L1 Checkpoint Inhibitors Sales by Region

6.1.1 APAC PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2026)

6.1.2 APAC PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2021-2026)

6.2 APAC PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026)

6.3 APAC PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe PD-1/PD-L1 Checkpoint Inhibitors by Country

7.1.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026)

7.1.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026)

7.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026)

7.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors by Country

8.1.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026)

8.1.2 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026)

8.2 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026)

8.3 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of PD-1/PD-L1 Checkpoint Inhibitors

10.3 Manufacturing Process Analysis of PD-1/PD-L1 Checkpoint Inhibitors

10.4 Industry Chain Structure of PD-1/PD-L1 Checkpoint Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 PD-1/PD-L1 Checkpoint Inhibitors Distributors

11.3 PD-1/PD-L1 Checkpoint Inhibitors Customer

12 WORLD FORECAST REVIEW FOR PD-1/PD-L1 CHECKPOINT INHIBITORS BY GEOGRAPHIC REGION

12.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size Forecast by Region

12.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Forecast by Region (2027-2032)

12.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global PD-1/PD-L1 Checkpoint Inhibitors Forecast by Type (2027-2032)

12.7 Global PD-1/PD-L1 Checkpoint Inhibitors Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Bristol Myers Squibb

13.1.1 Bristol Myers Squibb Company Information

13.1.2 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

13.1.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Bristol Myers Squibb Main Business Overview

13.1.5 Bristol Myers Squibb Latest Developments

13.2 Merck

13.2.1 Merck Company Information

13.2.2 Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

13.2.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Merck Main Business Overview

- 13.2.5 Merck Latest Developments
- 13.3 Regeneron Pharmaceuticals
 - 13.3.1 Regeneron Pharmaceuticals Company Information
 - 13.3.2 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.3.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Regeneron Pharmaceuticals Main Business Overview
 - 13.3.5 Regeneron Pharmaceuticals Latest Developments
- 13.4 Roche
 - 13.4.1 Roche Company Information
 - 13.4.2 Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.4.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Roche Main Business Overview
 - 13.4.5 Roche Latest Developments
- 13.5 Pfizer
 - 13.5.1 Pfizer Company Information
 - 13.5.2 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.5.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Pfizer Main Business Overview
 - 13.5.5 Pfizer Latest Developments
- 13.6 AstraZeneca
 - 13.6.1 AstraZeneca Company Information
 - 13.6.2 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.6.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 AstraZeneca Main Business Overview
 - 13.6.5 AstraZeneca Latest Developments
- 13.7 Hengrui Pharmaceuticals
 - 13.7.1 Hengrui Pharmaceuticals Company Information
 - 13.7.2 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.7.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Hengrui Pharmaceuticals Main Business Overview
 - 13.7.5 Hengrui Pharmaceuticals Latest Developments

13.8 Junshi Biosciences

13.8.1 Junshi Biosciences Company Information

13.8.2 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

13.8.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Junshi Biosciences Main Business Overview

13.8.5 Junshi Biosciences Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. PD-1/PD-L1 Checkpoint Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. PD-1/PD-L1 Checkpoint Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of PD-1 Inhibitors

Table 4. Major Players of PD-L1 Inhibitors

Table 5. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026) & (K Units)

Table 6. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026)

Table 7. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021-2026) & (\$ million)

Table 8. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2026)

Table 9. Global PD-1/PD-L1 Checkpoint Inhibitors Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Global PD-1/PD-L1 Checkpoint Inhibitors Sale by Application (2021-2026) & (K Units)

Table 11. Global PD-1/PD-L1 Checkpoint Inhibitors Sale Market Share by Application (2021-2026)

Table 12. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021-2026) & (\$ million)

Table 13. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2026)

Table 14. Global PD-1/PD-L1 Checkpoint Inhibitors Sale Price by Application (2021-2026) & (US\$/Unit)

Table 15. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Company (2021-2026) & (K Units)

Table 16. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Company (2021-2026)

Table 17. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Company (2021-2026) & (\$ millions)

Table 18. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Company (2021-2026)

Table 19. Global PD-1/PD-L1 Checkpoint Inhibitors Sale Price by Company

(2021-2026) & (US\$/Unit)

Table 20. Key Manufacturers PD-1/PD-L1 Checkpoint Inhibitors Producing Area
Distribution and Sales Area

Table 21. Players PD-1/PD-L1 Checkpoint Inhibitors Products Offered

Table 22. PD-1/PD-L1 Checkpoint Inhibitors Concentration Ratio (CR3, CR5 and CR10)
& (2024-2026)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Geographic Region
(2021-2026) & (K Units)

Table 26. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share Geographic
Region (2021-2026)

Table 27. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Geographic Region
(2021-2026) & (\$ millions)

Table 28. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by
Geographic Region (2021-2026)

Table 29. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Country/Region
(2021-2026) & (K Units)

Table 30. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by
Country/Region (2021-2026)

Table 31. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country/Region
(2021-2026) & (\$ millions)

Table 32. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by
Country/Region (2021-2026)

Table 33. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) &
(K Units)

Table 34. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country
(2021-2026)

Table 35. Americas PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country
(2021-2026) & (\$ millions)

Table 36. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026) & (K
Units)

Table 37. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026)
& (K Units)

Table 38. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2026) & (K
Units)

Table 39. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region
(2021-2026)

Table 40. APAC PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2021-2026) &

(\$ millions)

Table 41. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026) & (K Units)

Table 42. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026) & (K Units)

Table 43. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units)

Table 44. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026) & (\$ millions)

Table 45. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026) & (K Units)

Table 46. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026) & (K Units)

Table 47. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units)

Table 48. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2026)

Table 49. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026) & (K Units)

Table 50. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of PD-1/PD-L1 Checkpoint Inhibitors

Table 52. Key Market Challenges & Risks of PD-1/PD-L1 Checkpoint Inhibitors

Table 53. Key Industry Trends of PD-1/PD-L1 Checkpoint Inhibitors

Table 54. PD-1/PD-L1 Checkpoint Inhibitors Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. PD-1/PD-L1 Checkpoint Inhibitors Distributors List

Table 57. PD-1/PD-L1 Checkpoint Inhibitors Customer List

Table 58. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Forecast by Region (2027-2032) & (K Units)

Table 59. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 60. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 61. Americas PD-1/PD-L1 Checkpoint Inhibitors Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales Forecast by Region (2027-2032) & (K Units)

Table 63. APAC PD-1/PD-L1 Checkpoint Inhibitors Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Bristol Myers Squibb Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 73. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 74. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Bristol Myers Squibb Main Business

Table 76. Bristol Myers Squibb Latest Developments

Table 77. Merck Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 78. Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 79. Merck PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. Merck Main Business

Table 81. Merck Latest Developments

Table 82. Regeneron Pharmaceuticals Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 83. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 84. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K

Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. Regeneron Pharmaceuticals Main Business

Table 86. Regeneron Pharmaceuticals Latest Developments

Table 87. Roche Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 88. Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 89. Roche PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. Roche Main Business

Table 91. Roche Latest Developments

Table 92. Pfizer Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 93. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 94. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Pfizer Main Business

Table 96. Pfizer Latest Developments

Table 97. AstraZeneca Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 98. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 99. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. AstraZeneca Main Business

Table 101. AstraZeneca Latest Developments

Table 102. Hengrui Pharmaceuticals Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 103. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 104. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. Hengrui Pharmaceuticals Main Business

Table 106. Hengrui Pharmaceuticals Latest Developments

Table 107. Junshi Biosciences Basic Information, PD-1/PD-L1 Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 108. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolios and Specifications

Table 109. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 110. Junshi Biosciences Main Business

Table 111. Junshi Biosciences Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of PD-1/PD-L1 Checkpoint Inhibitors
- Figure 2. PD-1/PD-L1 Checkpoint Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. PD-1/PD-L1 Checkpoint Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country/Region (2025)
- Figure 10. PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of PD-1 Inhibitors
- Figure 12. Product Picture of PD-L1 Inhibitors
- Figure 13. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type in 2026
- Figure 14. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2026)
- Figure 15. PD-1/PD-L1 Checkpoint Inhibitors Consumed in Squamous Cell Skin Cancer
- Figure 16. Global PD-1/PD-L1 Checkpoint Inhibitors Market: Squamous Cell Skin Cancer (2021-2026) & (K Units)
- Figure 17. PD-1/PD-L1 Checkpoint Inhibitors Consumed in Non-small Cell Lung Cancer
- Figure 18. Global PD-1/PD-L1 Checkpoint Inhibitors Market: Non-small Cell Lung Cancer (2021-2026) & (K Units)
- Figure 19. PD-1/PD-L1 Checkpoint Inhibitors Consumed in Melanoma
- Figure 20. Global PD-1/PD-L1 Checkpoint Inhibitors Market: Melanoma (2021-2026) & (K Units)
- Figure 21. PD-1/PD-L1 Checkpoint Inhibitors Consumed in Gastric Cancer
- Figure 22. Global PD-1/PD-L1 Checkpoint Inhibitors Market: Gastric Cancer (2021-2026) & (K Units)
- Figure 23. PD-1/PD-L1 Checkpoint Inhibitors Consumed in Other
- Figure 24. Global PD-1/PD-L1 Checkpoint Inhibitors Market: Other (2021-2026) & (K

Units)

Figure 25. Global PD-1/PD-L1 Checkpoint Inhibitors Sale Market Share by Application (2025)

Figure 26. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application in 2026

Figure 27. PD-1/PD-L1 Checkpoint Inhibitors Sales by Company in 2026 (K Units)

Figure 28. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Company in 2026

Figure 29. PD-1/PD-L1 Checkpoint Inhibitors Revenue by Company in 2026 (\$ millions)

Figure 30. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Company in 2026

Figure 31. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Geographic Region (2021-2026)

Figure 32. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Geographic Region in 2026

Figure 33. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales 2021-2026 (K Units)

Figure 34. Americas PD-1/PD-L1 Checkpoint Inhibitors Revenue 2021-2026 (\$ millions)

Figure 35. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales 2021-2026 (K Units)

Figure 36. APAC PD-1/PD-L1 Checkpoint Inhibitors Revenue 2021-2026 (\$ millions)

Figure 37. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales 2021-2026 (K Units)

Figure 38. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue 2021-2026 (\$ millions)

Figure 39. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales 2021-2026 (K Units)

Figure 40. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue 2021-2026 (\$ millions)

Figure 41. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country in 2026

Figure 42. Americas PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2026)

Figure 43. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026)

Figure 44. Americas PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2026)

Figure 45. United States PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 46. Canada PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 47. Mexico PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 48. Brazil PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 49. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region in 2026

Figure 50. APAC PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2021-2026)

Figure 51. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026)

Figure 52. APAC PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2026)

Figure 53. China PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 54. Japan PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 55. South Korea PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 56. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 57. India PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 58. Australia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 59. China Taiwan PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 60. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country in 2026

Figure 61. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2026)

Figure 62. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026)

Figure 63. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2026)

Figure 64. Germany PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 65. France PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 66. UK PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 67. Italy PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$

millions)

Figure 68. Russia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 69. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2026)

Figure 70. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026)

Figure 71. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2026)

Figure 72. Egypt PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 73. South Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 74. Israel PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 75. Turkey PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 76. GCC Countries PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 77. Manufacturing Cost Structure Analysis of PD-1/PD-L1 Checkpoint Inhibitors in 2026

Figure 78. Manufacturing Process Analysis of PD-1/PD-L1 Checkpoint Inhibitors

Figure 79. Industry Chain Structure of PD-1/PD-L1 Checkpoint Inhibitors

Figure 80. Channels of Distribution

Figure 81. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Forecast by Region (2027-2032)

Figure 82. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share Forecast by Region (2027-2032)

Figure 83. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share Forecast by Type (2027-2032)

Figure 84. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share Forecast by Type (2027-2032)

Figure 85. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share Forecast by Application (2027-2032)

Figure 86. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global PD-1/PD-L1 Checkpoint Inhibitors Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G614EB0C728EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G614EB0C728EEN.html>